Seeking Alpha
 

St. Jude Medical, Inc. (STJ)

- NYSE
  • Aug. 16, 2012, 2:34 PM
    St. Jude Medical (STJ -3.5%) drops after the FDA orders a review of its Riata defibrillator leads. The agency recommends patients who have defibrillators with Riata leads should have x-rays or other imaging scans to check for abnormalities in the insulation surrounding the lead. STJ recalled the leads back in Nov. 2011; FDA says routine imaging may detect previously unrecognized abnormalities.
    | Aug. 16, 2012, 2:34 PM | Comment!
  • Aug. 1, 2012, 9:46 AM
    St. Jude Medical (STJ) declares $0.23/share quarterly dividend, in line with previous. Forward yield 2.44%. For shareholders of record Sep 28. Payable Oct 31. Ex-div date Sep 26. (PR)
    | Aug. 1, 2012, 9:46 AM | Comment!
  • Jul. 18, 2012, 8:53 AM
    More on St. Jude Medical (STJ -0.1%) Q2: net profit +1.2% to $244M, helped by reduced costs, although a weakness in the demand for heart-rhythm devices and forex effects weigh on earnings. Cuts FY EPS outlook by $0.04 to $3.40- $3.45 vs. consensus of $3.46. For Q3, forecasts $0.80-$0.82 vs. $0.83.
    | Jul. 18, 2012, 8:53 AM | Comment!
  • Jul. 18, 2012, 8:00 AM
    St. Jude Medical (STJ): Q2 EPS of $0.86 misses by $0.01. Revenue of $1.41B (-2.5% Y/Y). (PR)
    | Jul. 18, 2012, 8:00 AM | Comment!
  • Jul. 18, 2012, 12:05 AM
    Notable earnings before Wednesday’s open: ABT, APH, ASML, BAC, BK, BLK, BPOP, CHKP, DOV, ERIC, GWW, HON, KCG, NTRS, PNC, STJ, SWK, USB
    | Jul. 18, 2012, 12:05 AM | Comment!
  • Jul. 17, 2012, 5:30 PM
    Notable earnings before Wednesday’s open: ABT, APH, ASML, BAC, BK, BLK, BPOP, CHKP, DOV,ERIC, GWW, HON, KCG, NTRS, PNC, STJ, SWK, USB
    | Jul. 17, 2012, 5:30 PM | Comment!
  • Jul. 16, 2012, 9:27 AM
    St. Jude Medical (STJ) says that the erosion of leads for its recalled Riata defibrillator occurred from the inside out most often in cables with larger diameters, the initial findings of a study show. St. Jude faces a class action lawsuit over the leads.
    | Jul. 16, 2012, 9:27 AM | Comment!
  • Jun. 28, 2012, 11:32 AM
    The Supreme Court opinion on the Healthcare Act means that medical device makers still face a 2.3% tax on domestic sales starting next year unless they can persuade Congress to repeal it. Shares are sliding: MDT -1.2%, BSX -2.7%, STJ -1%, EW 1.1%, SYK -1.9%, ATRC -4.7%, CYBX -1.6%.
    | Jun. 28, 2012, 11:32 AM | 1 Comment
  • Jun. 25, 2012, 2:34 PM
    Goldman says that St. Jude's (STJ +0.2%) finding that its Durata lead failure was due to external abrasion means initial fears were unfounded and that the performance of the device will support further utilization and not lead to a major negative safety event. The firm continues to rate the shares a Buy. Additionally, Canaccord also reiterates a Buy, recommending investors add to positions.
    | Jun. 25, 2012, 2:34 PM | Comment!
  • Jun. 25, 2012, 11:41 AM
    St. Jude (STJ +0.2%) bucks a weak tape after saying late Friday it's identified a single Durata defibrillator lead that was damaged due to an external abrasion, but notes the lead did not have the critical flaw of an earlier version of the device that St. Jude no longer sells.
    | Jun. 25, 2012, 11:41 AM | Comment!
  • Jun. 22, 2012, 4:11 PM
    St. Jude Medical (STJ +2.6%) jumps at the close after a last-minute release of comments on a database report suggesting a single Durata defibrillation lead was damaged by external abrasion - different from the inside-out abrasion seen previously on Riata leads. (previously)
    | Jun. 22, 2012, 4:11 PM | Comment!
  • Jun. 18, 2012, 1:10 PM
    Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata defibrillator cable. A report turned up in an FDA database and was said to be due to a fraying issue, prompting fears that problems with STJ's earlier Riata product may not be isolated. But anyone can file to that database, Lazard says, and the cable wasn't returned to STJ for analysis.
    | Jun. 18, 2012, 1:10 PM | 3 Comments
  • Jun. 14, 2012, 7:32 PM
    A class action lawsuit charges St. Jude Medical (STJ) with misrepresenting facts around the company's Riata and Riata ST defibrillator leads (discontinued last year). Plaintiffs say protruding wires on those and other products caused short circuits that the company failed to disclose.
    | Jun. 14, 2012, 7:32 PM | Comment!
  • Jun. 12, 2012, 12:44 PM
    St. Jude Medical (STJ -5.5%) shares plunge suddenly on a report that the company's Durata defribilator is linked to a cable defect. STJ has had a similar problem with its Riata lead, which is no longer on the market; the company has said Durata leads, which it still sells, don't have the problem because they use a different type of insulation material.
    | Jun. 12, 2012, 12:44 PM | Comment!
  • May 31, 2012, 5:05 PM
    Dividend yields look increasingly attractive vs. record low Treasury yields, and Morgan Stanley argues the payout ratio of dividend stocks is near an all-time low and could increase substantially. The firm adds T to its dividend portfolio while removing XOM and UNP; "fundamentally and quantitatively attractive" are CVX, MET, FCX, BEN, CAH, FITB, STJ, SPLS.
    | May 31, 2012, 5:05 PM | 4 Comments
  • May 14, 2012, 1:26 PM
    St. Jude Medical (STJ +2.1%) ticks higher after being upgraded to Buy at Goldman. The firm cites share gains in its core markets and entrance into new therapeutic categories, which could accelerate revenue growth through 2015. It also raises its price target to $50 from $45.
    | May 14, 2012, 1:26 PM | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.